30 April 2020

12:00 p.m. ET

Register now!

Andrea Cossarizza, M.D., Ph.D.

University of Modena and Reggio Emilia School of MedicineModena, Italy

Maurice OGorman, Ph.D., M.B.A., (D)ABMLI

Children's Hospital Los Angeles,Los Angeles, CA

Lishomwa (Lish) Ndhlovu, M.D., Ph.D.

Weill Cornell MedicineNew York, NY

Sean Sanders, Ph.D.

Science/AAASWashington, DC

The COVID-19 pandemic has struck the global population with unparalleled speed and ferocity. Researchers around the world are scrambling to learn about the biology, pathology, and genetics of SARS-CoV-2the novel coronavirus responsible for COVID-19while clinicians are seeking treatments, old and new, that might slow its infectivity and deadliness. In this webinar, we will explore what scientists are learning by using flow cytometry to study patients with COVID-19 in order to elucidate risk and disease severity. These experts are global leaders in cytometry and infectious disease, working on the frontlines of the COVID-19 outbreaks. They will provide concrete examples of how flow cytometry has been harnessed to provide key laboratory evidence that can be used in the fight against SARS-CoV-2 and COVID-19. Viewers will have the opportunity to put their questions to the expert panel during the live broadcast.

During the webinar, attendees will:

This webinar will last for approximately 60 minutes.

University of Modena and Reggio Emilia School of MedicineModena, Italy

Dr. Cossarizza completed his M.D. degree at the University of Padova in Italy before receiving a Ph.D. in oncology from the University of Modena and Reggio Emilia (UNIMORE) and the University of Bologna, also in Italy. After specializing in clinical pathology at UNIMORE, he obtained an associate professorship there. In 2005, he was appointed a professor in the international Ph.D. program at the University of Valencia in Spain, where he later became a research professor. In 2010, he became a full professor in pathology and immunology in the Faculty of Medicine at UNIMORE. He is a member of several editorial boards of international journals, and in 2016 was elected president of the International Society for Advancement of Cytometry. His primary research focus is identifying the molecular and cellular basis for the involvement of the immune system in diseases and infections, including HIV/AIDS and sepsis, as well as its role in pathophysiological conditions related to aging and neurodegeneration. Dr. Cossarizza has notable experience in the development and use of new flow cytometry approaches in immunological research.

Children's Hospital Los Angeles,Los Angeles, CA

Dr. OGorman earned his Masters and Ph.D. at the University of British Columbia before completing a postdoctoral fellowship at the University of North Carolina at Chapel Hill. He then joined the faculty at the Feinberg School of Medicine at Northwestern University, during which time he earned his MBA from Northwestern and served as vice chair of Pathology and Laboratory Medicine and director of Diagnostic Immunology and Flow Cytometry at Childrens Memorial Hospital in Chicago. He is currently chief of laboratory medicine, as well as director of the Clinical Lab and the Diagnostic Immunology and Flow Cytometry Laboratory at Childrens Hospital Los Angeles, and a professor of pathology and pediatrics at the Keck School of Medicine of the University of Southern California. Dr. OGormans research interests include immunopathogenesis of immune systemrelated disorders, investigation of immune mechanisms of immune suppression withdrawal in liver transplant patients, and the development of novel immune-related diagnostic laboratory tests. Additionally, he provides ad hoc reviews for multiple journals, including Cytometry,Journal of Leukocyte Biology, Journal of Immunological Methods, Clinical and Diagnostic Laboratory Immunology, and Archives of Pathology & Laboratory Medicine.

Weill Cornell MedicineNew York, NY

Dr. Ndhlovu is a professor of immunology at Weill Cornell Medicine in New York and principal investigator of the HIV and Emerging Pathogens Immunopathogenesis Laboratory in the Division of Infectious Diseases, also at Weill Cornell. A translational immunologist, he leads a research team dedicated to confronting the challenges of HIV and aging, with an emphasis on limiting disease complications and developing curative strategies. His program is now bringing the same urgency and focus to the COVID-19 pandemic, using both single-cell and epigenetic approaches to resolve molecular mechanisms regulating viral entry of SARS-CoV-2 infection across different tissues and cell types. His work seeks to identify therapeutic host targets and future therapies that reduce morbidity and mortality, and relieve the burden of this disease on society. Dr. Ndhlovu completed his undergraduate degree at the University of Zambia, his medical training at the University of Zambia Medical School, and his doctorate at Tohoku University School of Medicine in Japan.

Science/AAASWashington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently, Dr. Sanders is the Director and Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Go here to read the rest:
Monitoring the immune system to fight COVID-19: CD4 status, lymphopenia, and infectivity - Science Magazine